News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025
Presentation ACC 2025 Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial Presenter: Darren K. McGuire March 29, 2025
News Conference News ACC 2021 Ticagrelor Monotherapy’s Benefits Extend to Women in TWILIGHT Yael L. Maxwell May 15, 2021
News Conference News ACC 2020 Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes Yael L. Maxwell March 30, 2020